Prostate Specific Membrane Antigen as Biomarker and Therapeutic Target for Prostate Cancer by Philipp Wolf
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Prostate Specific Membrane Antigen  
as Biomarker and Therapeutic  
Target for Prostate Cancer 
Philipp Wolf 
Department of Urology, University Medical Centre Freiburg  
Germany  
1. Introduction 
The Prostate Specific Membrane Antigen (PSMA) is considered to be the most well 
established target antigen in prostate cancer, since it is highly and specifically expressed at 
all tumor stages on the surface of prostate tumor cells. This chapter outlines the structure, 
function, and expression of PSMA, its relevance as prognostic and diagnostic biomarker, 
and different therapeutic approaches targeting this antigen. 
2. The Prostate Specific Membrane Antigen (PSMA) 
2.1 Structure, function and expression 
PSMA, also known as Glutamate Carboxypeptidase II (GCPII, EC 3.4.17.21), N-acetyl-┙-linked 
acidic dipeptidase I (NAALADase) or folate hydrolase, is a type II transmembrane protein, 
which is anchored in the cell membrane of prostate epithelial cells (Carter et al., 1996; Pinto et 
al., 1996). In 1998, the gene encoding PSMA was mapped to chromosome 11p11-p12, where it 
encompasses 19 exons spanning about 60 kb of genomic DNA (O'Keefe et al., 1998). The 
cDNA of PSMA codes for a glycoprotein of 750 amino acids (aa) with a molecular mass of 
about 100 kDa. The protein is partitioned into a small intracellular domain of 19 aa, a 
transmembrane domain of 21 amino acids, and a large extracellular domain of 707 aa. 
Crystallization data revealed that the extracellular domain of PSMA folds into three distinct 
structural and functional domains: a protease domain (aa 56-116), an apical domain (aa 117-
351), and a C-terminal domain (aa 592-750). Furthermore, it was shown that PSMA is 
expressed as a compact homodimer, which is highly glycosylated with oligosaccharides 
accounting up to 25% of the molecular weight (Davis et al., 2005; Mesters et al., 2006).  
PSMA contains a binuclear zinc site and can act as glutamate carboxypeptidase or folate 
hydrolase, catalyzing the hydrolytic cleavage of glutamate from poly-┛-glutamated folates 
(Ghosh & Heston, 2003). Therefore, PSMA is thought to play a role in the folate metabolism 
of the prostate. This hypothesis is supported by recent studies, where PSMA expression 
correlated with proliferation and folate uptake of PSMA transfected cells (Yao & Bacich, 
2006; Yao et al., 2009). 
In contrast to other prostate-related antigens, like prostate specific antigen (PSA), prostate 
acidic phosphatase (PAP) or prostate secretory protein (PSP), PSMA is not secreted into 
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circulation. Instead of that, PSMA undergoes constitutive internalization, which is about 
threefold enhanced after antibody binding (Liu et al., 1998). It is therefore suggested that 
PSMA has transport function and that anti-PSMA antibodies might act as surrogates for a 
yet unknown ligand. The endocytic pathways of PSMA after antibody binding were 
specified in a recent study and comprise clathrin-mediated endocytosis, macropinocytosis, 
and clathrin-, calveolae-independent endocytosis (Liu et al., 2009b). 
To examine the PSMA expression in the prostate, immunohistochemical analyses were 
performed.  In a study with prostate tissue specimen from 184 patients with prostate cancer, 
the percentage of PSMA positive stained cells averaged about 69.5% (range 20%-90%) in the 
benign epithelium, 77.9% (range 30-100%) in high grade prostatic intraepithelial neoplasia 
(PIN) and was highest in adenocarcinomas with a mean of 80.2% (range 30-100%). In 
contrast, tumor stroma, urothelium, normal vasculature and, with rare exceptions, basal 
cells were PSMA negative (Bostwick et al., 1998). Other immunohistochemical studies 
demonstrated a heterogeneous, weak to moderate staining of normal prostate epithelial 
cells, and a homogeneous, extensive staining of prostate adenocarcinomas and metastases 
(Silver et al., 1997; Wolf et al., 2010a).  
PSMA expression is highly organ specific. An extraprostatic expression was only detected in 
secretory cells of the salivary glands (Israeli et al., 1994; Troyer et al., 1995; Wolf et al., 
2010a), in cryptic cells of the duodenal brush border (Chang et al., 1999; Wolf et al., 2010a), 
and in a subset of proximal renal tubules (Liu et al., 1997; Silver et al., 1997; Chang et al., 
1999). In some studies, an additional expression was found in the brain and in the colon, but 
these results are controversially discussed (Troyer et al., 1995; Silver et al., 1997; Chang et al., 
1999; Sacha et al., 2007). Nonetheless, potential side effects of anti-PSMA therapeutics 
against PSMA expressing normal organs were not described until today. 
Interestingly, PSMA is also discussed as an unique anti-angiogenetic target, since it is 
expressed in the neovascularization of numerous solid tumors (bladder, kidney, breast, 
pancreas, lung, melanoma), but not in normal blood vessels (Liu et al., 1997; Chang et al., 
1999; Chang et al., 2001; Baccala et al., 2007). In this respect, it was found that PSMA 
regulates cell invasion and tumor angiogenesis by modulating integrin signal transduction 
in endothelial cells (Conway et al., 2006). 
2.2 PSMA as prognostic and diagnostic biomarker 
Generally, prostate carcinoma tissues show a higher PSMA expression and an increased 
enzymatic activity of PSMA compared with normal prostate and benign prostate 
hyperplasia (BPH) tissues (Lapidus et al., 2000; Burger et al., 2002). Therefore, the 
question was raised, if PSMA might serve as a valuable biomarker for the management of 
prostate cancer. 
Indeed, in different studies a direct correlation between PSMA expression and the 
Gleason score, which is used for the staging of prostate cancer, was determined for 
adenocarcinomas (Su et al., 1995; Kawakami & Nakayama, 1997; Burger et al., 2002). 
Moreover, an upregulation of PSMA was shown in tumor cells of patients with hormone-
refractory prostate cancer (Wright et al., 1996; Kawakami & Nakayama, 1997). In a study 
with tissue specimen from 136 patients it was demonstrated that PSMA can serve as a 
prognostic biomarker, because it significantly correlates with adverse prognostic factors, 
like tumor grade, pathological stage, aneuploidy, and biochemical recurrence, and 
therefore independently predicts disease outcome (Ross et al., 2003).  
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Recently, a new splice variant (PSM-E) was described, which is specifically overexpressed in 
prostate carcinomas and which correlates with the Gleason score (Cao et al., 2007). PSM-E, 
which is expressed in the cytoplasm, could account for the lack of correlation between 
histological positive staining of anti-PSMA antibodies with clinical grade (stage) 
(Mannweiler et al., 2009). 
Despite of such controversies, it is apparent that the enhanced expression and enzymatic 
activity of PSMA in aggressive prostate tumors is indicative of a selective advantage on the 
part of cells expressing it and that it contributes to prostate carcinogenesis. 
PSMA was found to associate with the anaphase-promoting complex and to induce 
chromosomal instability (Rajasekaran et al., 2008). Moreover, PSMA favoured prostate 
cancer development in a permissive folate environment (Yao & Bacich, 2006; Yao et al., 
2009). One mechanism by which PSMA contributes to prostate tumor growth is its ability to 
activate IL-6 and CCL5 synthesis. These cytokines acted synergistically to enhance the 
growth of LNCaP cells by activating the MAPK pathway (Colombatti et al., 2009). 
Taken together, assessment of PSMA levels, either alone or in combination with PSA status, 
might prove useful in future for the diagnosis of metastatic prostate cancer, risk assessment, 
and the prognosis of disease outcome. 
2.3 PSMA as therapeutic target 
Specific characteristics of PSMA concerning its structure, function and expression make it an 
ideal candidate as a target antigen for the treatment of advanced prostate cancer. (1) Its high 
and specific expression on the prostate cancer cell surface and the fact that it is not shed into 
the circulation allows an effective systemic delivery of PSMA targeting therapeutics. (2) Its 
high organ specificity leads to a minimal binding of anti-PSMA drugs to normal organs and 
therefore to a maximal reduction of potential side effects. (3) Its expression at all tumor 
stages enables a therapeutic intervention at any time of the disease. (4) Its internalization 
after ligand binding can be used for the targeted delivery of intracellular acting drugs. (5) Its 
enzymatic activity allows the cleavage of prodrugs to active molecules on the surface of 
prostate cancer cells. 
Many preclinical and clinical studies were performed in the last years, which used PSMA as 
target antigen. They include radioimmunotherapy, the use of immunotoxins, targeted 
virotherapy, retargeting of immune cells, PSMA vaccination, prodrug activation, 
photodynamic therapy, and PSMA targeting nanoparticles. 
2.3.1 Anti-PSMA radioimmunotherapy 
Radioimmunoconjugates generally consist of an antibody moiety as target domain coupled 
to a therapeutic radionuclide (alpha- or beta-particle) with the biologic effect of high linear 
energy transfer (LET) radiation. Compared to conventional radiotherapy, 
radioimmunoconjugates allow the targeted delivery of reduced radiation doses to the 
tumor, which ideally leads to a reduction of side effects. Moreover, the radiation of a 
radioimmunoconjugate is not restricted to cells presenting the target antigen. It also affects 
neighboring cells with a heterogeneous antigen expression or insufficient vascularization, 
which is so called “bystander effect” (Rzeszowska-Wolny et al., 2009). 
An initial immunoscintigraphic approach targeting PSMA was done with the 111Indium 
(111In) labeled anti-PSMA monoclonal antibody 7E11 (Capromab Pendetide (Prosta Scint®), 
Cytogen, Philadelphia, PA) (Kahn et al., 1994; Sodee et al., 1996; Kahn et al., 1998). With this 
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radioimmunoconjugate a higher sensitivity was reached in the imaging of prostate cancer 
soft tissue metastases compared to Computed Tomography (CT) or Magnetic Resonance 
Tomography (MRT) (Murphy et al., 1998). Therefore, Prosta Scint® received approval from 
the U.S. Food and Drug Administration (FDA) for the detection and imaging of prostate 
cancer soft tissue metastases (Rosenthal et al., 2001). The reason, why Prosta Scint® is only 
suitable for the detection of soft tissue metastases, is based on the fact that the 7E11 antibody 
recognizes an intracellular epitope of PSMA. Therefore, it can not bind to viable tumor cells, 
but only to PSMA molecules in damaged, dead or dying cells. Lymph node or bone 
metastatic lesions tend to be relatively small and do not characteristically own a high 
percentage of apoptotic or necrotic cells. Indeed, in a radioimmunotherapeutic trail with the 
90Yttrium-(90Y) labeled 7E11, no objective or biochemical remissions could be measured (Deb 
et al., 1996; Kahn et al., 1999). 
Therefore, monoclonal antibodies, which bind to the extracellular domain of PSMA, were 
used for the construction of radioimmunoconjugates in subsequent studies. Three anti-
PSMA antibodies, called 3/A12, 3/E7, and 3/F11, which recognize different extracellular 
epitopes, were labeled with 64Copper (64Cu) and used for Positron Emission Tomography 
(PET) imaging of human prostatic tumors in the SCID mouse xenograft model. Whereas 
excellent tumor uptakes of all antibodies between 31.6 and 35.1%ID/g were measured in 
tumors of the PSMA expressing androgen-independent LNCaP subline C4-2, only activities 
at background levels were detected in PSMA negative DU 145 control xenografts (Elsasser-
Beile et al., 2009; Alt et al., 2010). In a first preclinical experiment, the antibody 3/F11 was 
labeled with the beta particle emitter 177Lutetium (177Lu) and was used for the 
radioimmunotherapy of mice bearing C4-2 tumors xenografts. Biodistribution studies 
revealed a tumor to muscle ratio of more than 70 and a tumor to blood ratio of more than 4.5 
after 72 h. Treatment of mice with the conjugate resulted in tumor growth inhibition and in 
a more than 2-fold enhanced survival after application of a single dose of 1 MBq. However, 
in this study the therapeutic window was small, because mice treated with a dose of 2 MBq 
apparently died of myelotoxicity (Behe et al., 2011).  
Another panel of antibodies binding to extracellular PSMA (J415, J533, and J591) was tested 
in preclinical and clinical trials for radioimmunotherapy. J591 was labeled with the alpha 
particle emitter 213Bismuth (213Bi), which is well suited for the radiation of single cell 
neoplasms and micrometastases in a range between 0.07 and 0.1 mm. [213Bi]J591 caused a 
high cytotoxicity against LNCaP cells in vitro. In vivo, a significant improvement of tumor 
free survival in nude bearing LNCaP tumors was reached, which was accompanied by a 
significant reduction of PSA serum levels (McDevitt et al., 2000). In another study, the 
biodistribution of the 131Iod (131I) labeled antibodies J591, J415, and 7E11 was examined. 
High tumor uptakes were measured with all antibodies in LNCaP tumor xenografts, which 
were up to 20-fold higher than in PSMA negative DU 145 or PC-3 tumors. Autoradiographic 
studies showed that the extracellular binding antibodies J415 and J591 preferentially 
recognized areas of viable tumor cells, whereas the intracellular binding antibody 7E11 
mainly detected necrotic tumor areas (Smith-Jones et al., 2003). 
The antibody J591 was chosen for further radioimmunotherapeutic experiments. To reduce 
a possible immunogenicity of the mouse antibody in prostate cancer patients, J591 was 
humanized by site directed mutagenesis of putative B- and T-cell epitopes of the variable 
domains and by exchanging the mouse constant domains into human ones. The humanized 
antibody J591 (huJ591) was then labeled with 131I and 90Y. Doses of 3.7 to 11.1 MBq 131I-hu591 
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and of 3.7 to 4.7 MBq 90Y-hu591 led to a reduction of mean tumor volumes between 15 and 
90% in nude mice bearing LNCaP tumors. Additionally, both radioimmunoconjugates 
effected an 2 to 3-fold increase of median survival relative to untreated controls 
(Vallabhajosula et al., 2004).  
In a first phase I clinical trail, prostate cancer patients initially received the 111In-labeled 
huJ591 for immunoscintigraphy followed by application of 90Y-huJ591 for therapy. With 
111In-huJ591 total body images demonstrated a significant metabolism of the 
radioimmunoconjugate in the liver and to a lesser extend in the kidneys and spleen. 
Additionally, bone and soft tissue metastases were efficiently targeted. One week later, 
90Y-huJ591 was applicated and a maximal tolerated dose (MTD) of 17.5 mCi/m² could be 
determined. PSA stabilisation was noted in 6/29 patients and 2 patients showed a PSA 
decline of 70 and 85% lasting 8 and 8.6 months, respectively (Milowsky et al., 2004). Another 
cohort of 35 patients received 177Lu-labeled huJ591 at doses between 10 and 75 mCi/m². 
Blood and urinary pharmacokinetics were similar to those of 90Y-huJ591. But the MTD of 
70 mCi/m² was about 4-fold higher. Patients treated with 75 mCi/m² 177Lu-huJ591 
developed grade 3 and 4 thrombocytopenia and grade 4 neutropenia, but retreatment with 
30 mCi/m² was well tolerated. In 4 patients a PSA decline of more than 50% and in 16 
patients a PSA stabilisation was noted (Milowsky et al., 2004). In both clinical trials with 
radiolabeled huJ591 myelosuppression was dose-limiting. Whereas no clear correlation 
between myelotoxicity and therapeutic dose was determined for 90Y-huJ591, myelotoxicity 
and especially thrombocytopenia correlated well with the applicated doses and the bone 
marrow doses for 177Lu-huJ591 (Vallabhajosula et al., 2005). 
To verify PSMA as a target for an anti-angiogenesis therapy, 111In-huJ591 was used for the 
imaging of known metastases in patients with different solid tumors. Indeed, this 
radioimmunoconjugate showed a high uptake in metastases of 7/10 kidney cancer 
patients, 4/4 colon carcinoma patients, 3/3 lung cancer patients, 3/3 pancreatic cancer 
patients, 1/3 bladder cancer patients, 2/3 breast cancer patients, and 1/1 melanoma 
patient (Milowsky et al., 2007).  
2.3.2 Anti-PSMA immunotoxins 
PSMA was also used as a target for the generation of immunotoxins against prostate cancer. 
Immunotoxins are constructs, where a PSMA binding domain (antibody, antibody 
fragment, RNA aptamer, peptide) is coupled to a toxin domain. The toxin domain is 
targeted by the PSMA binding domain to the prostate cancer cell and is cytotoxic after 
internalization.  
Ricin from Ricinus communis acts as a very common toxin for the construction of 
immunotoxins. It consists of the ricin A chain and the ricin B chain held together by a 
disulfide bond. The ricin A chain is the enzymatically active subunit, which inactivates the 
protein biosynthesis machinery by irreversible hydrolysis of the N-glycosidic bond of an 
adenine (A4324) within the 28S rRNA. The ricin B chain binds ubiquitous to cell surface 
structures and facilitates membrane translocation and intracellular trafficking of the ricin A 
chain (Sandvig et al., 2002).  
The first generation of anti-PSMA immunotoxins was made by chemically coupling of anti-
PSMA antibodies to ricin A. An immunotoxin consisting of J591 and ricin A elicited a 50% 
reduction in cell viability (IC50) of LNCaP cells at a concentration of about 265 pM and 
showed a more than 5000-fold potentation of cytotoxicity compared to the unconjugated 
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ricin A chain (Fracasso et al., 2002). For another ricin A-based immunotoxin with the rat 
monoclonal antibody E6 an IC50 value of 60 pM was measured. Additionally, a significant 
inhibition of LNCaP tumor growth in the mouse xenograft model was reached with this 
molecule (Huang et al., 2004).  
In a recent study, the humanized antibody huJ591 was linked to the plant toxin saporin. 
Saporin is produced is seeds and leaves of the plant Saponaria officinalis and belongs to class I 
ribosome inactivating proteins. With the saporin-based immunotoxin, a percentage of 60.3% 
apoptotic cells and an IC50 value of 140 pM was determined on LNCaP cells after 72 h 
incubation. Furthermore, a significant inhibition of tumor growth was measured in the LNCaP 
tumor xenograft model. However, due to its high molecular weight of about 280 kDa, the 
immunotoxin is thought to have a high immunogenicity and a limited diffusion into tumor 
tissues. Therefore, further development is focused on saporin-based constructs of smaller 
size less inherent immunogenicity (Kuroda et al., 2010). 
The anti-PSMA antibody J591 was also used for the construction of an immunotoxin 
containing the melittin-like peptide 101 from honey bee (Apis mellifera) venom. This construct 
successfully inhibited the growth of LNCaP-LN3 tumors and led to a slight improvement of 
the median survival of treated mice. However, the high affinity of peptide 101 to lipid bilayer 
membranes also led to a high non-specific cytotoxicity (Russell et al., 2004). 
A further immunotoxin was generated by coupling huJ591 to the chemotherapeutic drug 
maytansinoid 1 (DM1) (Henry et al., 2004), which is a microtubule-depolymerizing analogue 
of maytansine (Chari et al., 1992). Maytansine is a naturally occurring ansa macrolide and 
was evaluated as a chemotherapeutic agent in the 1970s and 1980s. Unfortunately, 
maytansine caused severe, dose-limiting gastrointestinal and central neurological toxicities 
and was therefore not developed further (Blum et al., 1978). With the DM1-based anti-PSMA 
immunotoxin, called MLN2704, a growth delay of CWR22Rv1 tumor xenografts of more 
than 100 days was achieved at an optimized dosage schedule of 60 mg/kg every 14 days 
(Henry et al., 2004). MLN2704 was also tested in a clinical phase I trial in 9 patients with 
prostate cancer. Two of these patients, treated with 264 or 343 mg/m² immunotoxin 
respectively, had a more than 50% decrease in their PSA serum level. Additionally, the 
patient treated with 264 mg/m² showed a measurable tumor regression (Galsky et al., 2008). 
In another approach, a fully human anti-PSMA antibody was generated in transgenic mice 
and was conjugated to monomethylauristatin E (MMAE), which is a potent inhibitor of 
tubulin polymerization. With this construct IC50 values of 83 pM on LNCaP cells and of 
65 pM on C4-2 cells could be determined. Furthermore, a significant improvement of the 
median survival of tumor bearing mice 9-fold relative to the controls was reached without 
any signs of toxicity. Interestingly, 2/5 animals treated with a maximal dose of 6 mg/kg 
immunotoxin had no detectable tumor or measurable PSA at day 500 and could therefore 
considered as cure (Ma et al., 2006).  
Obstacles of chemically conjugated immunotoxins to be optimal therapeutic agents 
comprise a high immunogenicity, a possible influence of chemical modifications on antigen 
binding, and inhomogeneous preparations. This can, at least in part, be overcome by second 
generation, recombinant immunotoxins. 
For the construction of the first recombinant immunotoxin against PSMA, an anti-PSMA 
single chain antibody fragment (scFv), consisting of one variable domain of the heavy chain 
(VH) and one variable domain of the light chain (VL) connected by a flexible linker, was 
generated from the monoclonal antibody 3/A12 by phage display. This scFv was called A5. 
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As toxin domain, the truncated form of Pseudomonas exotoxin A (PE40), consisting of the 
transmembrane domain and the enzymatically active domain of the toxin, was used. The 
virulence factor Pseudomonas Exotoxin A from the human pathogenic bacterium 
Pseudomonas aeruginosa is able to ADP-ribosylate the eukaryotic elongation factor 2 (eEF-2) 
of a target cell, which leads to the inhibition of protein biosynthesis and finally to apoptosis 
(Wolf & Elsasser-Beile, 2009). The bacterially expressed anti-PSMA immunotoxin, called A5-
PE40, specifically bound to prostate cancer cells with IC50 values in the low pM range. 
Moreover, it induced a significant growth inhibition of C4-2 tumors in the SCID mouse 
xenograft model (Wolf et al., 2006; Wolf et al., 2008).  
A similar immunotoxin was recently generated by using the scFv D7 from the anti-PSMA 
antibody 3/F11. This immunotoxin, termed D7-PE40, also showed a high binding to C4-2 
cells and led to a significant growth inhibition of subcutaneously implanted tumors. In 
toxicity studies, D7-PE40 was well tolerated in mice at single, but at higher doses the 
immunotoxin was lethal. Blood analyses indicated that the death of the animals was based 
on a severe hepatotoxicity, which was marked by increased aspartate transaminase (AST) 
and alanine transaminase (ALT) serum levels. Histopathological examinations revealed a 
marked damage of the hepatic parenchyma with disappearance of sinusoidal structures 
based on apoptosis and vacuolar degeneration of hepatocytes (Wolf et al., 2010b). 
Hepatotoxicity is a very common side effect of Pseudomonas Exotoxin A based 
immunotoxins and is presumably attributed to a TNF-alpha release of Kupffer cells (Onda et 
al., 1999). Different strategies are therefore under investigation to reduce the hepatotoxicity, 
e.g. by PEGylation or lowering of the isoelectric points of the immunotoxins (Onda et al., 
2001). Another main research comprises the reduction of the immunogenicity by elimination 
of immunodominant B-cell epitopes (Onda et al., 2006).   
Alternatively to antibodies or antibody fragments, RNA aptamers can be used for the 
construction of immunotoxins, which are considered to be advantageous with respect to a 
higher stability, ease of synthesis and lower production costs. One immunotoxin was 
constructed by coupling of an anti-PSMA RNA aptamer to the plant toxin gelonin from 
Gelonium multiflorum, which has high N-glycosidase activity on the 28S RNA unit of 
eukaryotic ribosomes. This molecule was found to be toxic against prostate cancer cells with 
an IC50 value of 27 nM (Onda et al., 2006). 
Recently, a chemical ligand, termed 2-[3-(1,3-dicarboxypropyl)ureido] pentanedioic acid 
(DUPA), was synthesized that selectively binds to PSMA (Kularatne et al., 2010). After 
coupling to different chemotherapeutic drugs, this molecule was capable to mediate the 
targeted killing of LNCaP cells (Kularatne et al., 2010). 
2.3.3 Targeted virotherapy 
In a recent study, measles viruses of a live attenuated strain were used for a targeted anti-
PSMA virotherapy (Liu et al., 2009a). Measles viruses are very effective against a variety of 
tumor types, including prostate cancer (Blechacz & Russell, 2008; Msaouel et al., 2009). 
Generally, measles viruses infect host cells via one of two measles receptors, CD64 or SLAM. 
CD64 is ubiquitously present on the surface of human cells, whereas SLAM is expressed on 
immune cells. The viruses take their oncolytic effect by induction of an extensive 
intracellular fusion between infected cells and neighboring cells to form non-viable 
multinucleated structures (syncytia). For the construction of the virotherapeutic conjugate, 
called MVG-┙PSMA, the anti-PSMA antibody huJ591 was coupled to a coat protein of 
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measles virus, in which alanine substitutions of specific residues ablated the viral interaction 
with CD64 and SLAM. After propagation and infection, a MVG-┙PSMA mediated 
cytopathic killing of PSMA expressing LNCaP and PC3/PIP cells was detected. Moreover, a 
regression or growth inhibition of tumor xenografts could be achieved (Msaouel et al., 2009). 
A crucial obstacle for a future clinical use of MVG-┙PSMA could be pre-existing anti-viral 
antibodies in patients, who have been vaccinated or infected by wild type measles viruses. 
These antibodies might quickly neutralize the virus domain after application. Therefore, 
efforts are undertaken to circumvent the problem, e.g. by intratumoral application of the 
construct, by hiding the virus in cell carriers, or by the use of immunosuppressive drugs to 
dampen the patient’s immune response (Liu et al., 2009a). 
2.3.4 Retargeting of immune cells 
The therapeutic concept of immune cell retargeting comprises the activation of T 
lymphocytes for the targeted cytolysis of tumor cells. For the retargeting of prostate cancer 
cells via PSMA, two strategies were pursued: the construction of diabodies and the 
generation of fusion receptors. 
Generally, diabodies for T cell retargeting consist of two antibody domains. One domain 
binds to the tumor antigen and the other one to a T cell activating antigen. The diabody 
builds a bridge between the tumor cell and the immune effector cell, which then triggers the 
cytotoxic responses that include perforin and granzyme release.  
Anti-PSMA diabodies were constructed by fusing the anti-PSMA scFvs A5 or D7 to a scFv 
against the CD3 T cell receptor. With these constructs, a retargeting of CD4+ and CD8+ 
blood lymphocytes with subsequent lysis of C4-2 cells was obtained. Moreover, a significant 
inhibition of C4-2 tumor growth could be achieved (Buhler et al., 2008; Buhler et al., 2009; 
Fortmuller et al., 2011).  
A fusion receptor targeting PSMA, also referred to as chimeric antigen receptor (CAR), was 
generated by coupling an anti-PSMA scFv to the zeta-chain of the CD3 T-cell receptor. The 
CAR can be expressed at the surface of CAR-transfected T cells. Then the CAR can recruit 
and activate the T cell by binding to PSMA. This mechanism is independent of a human 
leukocyte antigen expression. Using CAR transfected peripheral blood lymphocytes, a 
specific killing of PSMA-expressing prostate cancer cells and an elimination of 
orthotopically or subcutaneously implanted PSMA-positive tumors was reached (Gade et 
al., 2005). In a subsequent study, the effects of CAR could be optimized by adding combined 
CD28 and 4-1BBL costimulatory signaling domains. With this strategy, an enhanced 
cytokine release, a higher in vivo T cell survival, and an enhanced anti-tumor activity could 
be measured in tumor bearing SCID mice (Zhong et al., 2010). 
A similar fusion receptor against PSMA, designated as chimeric immunoglobulin T-cell 
receptor (IgTCR), was also used for the retargeting of immune cells. IgTCR consists of an 
anti-PSMA scFv from the monoclonal antibody 3D8 and a signaling portion of the CD3 zeta 
chain. IgTCR transfected T-cells were activated after PSMA binding, which was followed by 
cytokine release and specific lysis of the prostate cancer cells. Additionally, this molecule 
showed a high anti-tumor activity in a mouse xenograft model (Ma et al., 2004).  
2.3.5 PSMA vaccination 
Vaccination with PSMA peptides, which aims for boosting the patient’s immune response 
against PSMA expressing tumor cells, represent another weapon in the battle against 
prostate cancer. One approach utilizes the patient’s dentritic cells (DCs), to present PSMA 
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peptides in association with the MHC class I peptide complex to naïve cytotoxic T 
lymphocytes (CTL) (Melief, 2008). For DC preparation, patients were leucophoresed, and 
peripheral blood mononuclear cells (PBMCs) were isolated. Adherent cells were 
differentiated with GM-CSF and IL-4. Then the obtained DCs were pulsed with recombinant 
PSMA peptides, which were identified in function of their ability to recruit CTLs and to be 
recognized as CTL targets. In a first phase I/II clinical trial involving 33 prostate cancer 
patients, 9 partial responders were identified with an average response duration of 225 days 
(Tjoa et al., 1998). In a phase II study, 2/33 patients with hormone refractory metastatic 
disease showed a complete response and another 6 patients a partial response (Murphy et 
al., 1999). In another clinical trial with 37 patients, one complete and 10 partial responses 
were identified (Salgaller et al., 1998; Tjoa et al., 1999).  
Two subsequent protocols used DCs to present a PSMA peptide in combination with 
peptides from other tumor antigens to treat hormone-refractory patients. In one study, CTL 
responses and transient decline of serum PSA was observed in 4/8 patients, who received 4 
intradermal vaccinations every other week (Fuessel et al., 2006). In the other study, 3 
patients were administered with 6 vaccines intradermally at biweekly intervals and showed 
partial remissions. However, no CTL response against the PSMA peptide could be observed 
(Waeckerle-Men et al., 2006). The same PSMA peptide was loaded as a single peptide to 
PBMCs, which were used to treat 12 patients with hormone-resistant tumors. However, no 
clinical advantages were observed and no immune responses were detected in this trial 
(Knight et al., 2009). 
A further development was the transfection of DCs with plasmids containing the 
extracellular domain of PSMA to activate autologous lymphocytes in an in vitro model. 
Indeed, PSMA-expressing DCs were able to generate antigen-specific cytotoxic T cell 
responses (Mincheff et al., 2003).   
In a recent study, replication deficient adenoviruses were used to introduce a truncated 
form of PSMA and the T cell stimulatory molecule 4-1BBL into murine DCs. After infection 
of the DCs, PSMA-specific proliferative responses and an upregulation of CD80 and CD86 
costimulatory molecules were detected. Moreover, vaccination of mice with the transfected 
DCs induced a potent protective and therapeutic anti-tumor immunity (Kuang et al., 2010). 
Other strategies for PSMA vaccination are the application of DNA plasmids or viral 
immunizations. In a phase I study, prostate cancer patients were intradermally immunized 
with an expression plasmid or a replication-defective adenoviral vector bearing the PSMA 
gene according to six different drug regimens. All vaccinations were well tolerated and no 
immediate- or long-time side effects were reported (Mincheff et al., 2000). Anti-PSMA 
antibodies were found in 21% of patients at baseline and in 12-50% of patients at longitudinal 
time points ranging from 3 to 36 months after immunization (Todorova et al., 2005).  
In a preclinical study it was shown that immunization of mice with xenogenic PSMA 
protein followed by a boosting with a vector that encoded autologous PSMA gave the best 
protection (Mincheff et al., 2006). These data provided the basis for a clinical study with 
DNA plasmid vaccines, in which 36 patients with recurrent prostate cancer received three 
vaccinations with mouse or human PSMA. Vaccination was well tolerated and PSA serum 
levels were maximally reduced at the highest dose level (Gregor et al., 2007). 
2.3.6 Prodrug activation 
The glutamate carboxy peptidase activity of PSMA can be used for the activation of 
prodrugs to a fully active compound on the surface of prostate cancer cells. Different 
www.intechopen.com
 
Prostate Cancer – Diagnostic and Therapeutic Advances 
 
90
methotrexate-based peptide analoges were screened to identify PSMA selective substrates 
that are stable to unspecific hydrolysis in human and mouse plasma. Analogs containing 
┙-linked or ┛-linked glutamic or aspartic acids were most efficiently hydrolyzed by PSMA to 
release the cytolytic anti-metabolite methotrexate. As a consequence thereof, these analoges 
showed the highest cytotoxicity against PSMA-expressing prostate cancer cells (Mhaka et 
al., 2004). In a subsequent study, these peptides were coupled to a cytotoxic analogue of the 
plant toxin thapsigargin that induces apoptosis by inhibition of the endoplasmatic reticulum 
Ca-ATPase pump. PSMA hydrolysis of these peptide prodrugs led to a cytotoxicity against 
PSMA-positive prostate cancer cells that was 10- to 60-fold higher than against PSMA-
negative ones. One of these prodrugs was also tested in mice with CWR22H xenografts and 
elicited tumor growth delay or tumor regressions following a single 3-day or 10-day course 
of administration (Mhaka et al., 2006). 
2.3.7 Photodynamic therapy 
The lack of specific delivery of photosensitizers, chemical compounds that can be excited by 
light of a specific wavelength for the destruction of tumor tissues, represents a significant 
limitation for photodynamic therapies (PDT). Therefore, a conjugate was generated 
containing the photosensitizer pyropheophorbide-a and a PSMA inhibitor for the treatment 
of prostate cancer. This construct demonstrated a high and specific cytotoxicity against 
LNCaP cells after irradiation, whereas PSMA-negative PC-3 cells remained unaffected. PDT-
mediated effects of the photodynamic conjugate were extensively studied and involved cell 
membrane permeabilization, rapid disruption of microtubules (┙-/┚-tubulin), 
microfilaments (actin), and intermediate filaments (cytokeratin 8/18) in the cytoplasm, 
activation of caspase-3, -8, and -9, Poly [ADP-ribose] Polymerase (PARP)-cleavage, and 
DNA fragmentation (Liu et al., 2009c; Liu et al., 2010a; Liu et al., 2010b). 
2.3.8 Nanoparticles targeting PSMA 
Nanotechnology represents a new alternative for the treatment of prostate cancer. The 
production of nanoparticles enables the targeted delivery and controlled release of 
thousands of drug molecules per vehicle into the tumor cells and is a promising strategy to 
overcome the lack of specificity and limited efficacy of conventional chemotherapeutic 
agents. 
One of the first therapeutic nanoparticle against prostate cancer was a docetaxel-
encapsulated nanoparticle formulated with biocompatible and biodegradable poly(D,L-
lactic acid-co-glycolic acid)-block-poly(ethyleneglycol) copolymer (PLGA-b-PEG), which 
surface was derivatized with the anti-PSMA RNA-aptamer A10. With this construct, an 
enhanced cytotoxicity, compared to non-targeted nanoparticles that lack the aptamer, was 
shown. After a single intratumoral injection, the nanoparticle elicited a complete tumor 
reduction in 5/7 mice with LNCaP tumor xenografts of about 300 mm³ in size. The survival 
rate of these mice in a 109 days study was 100%, compared to 57% of mice treated with the 
non-targeted nanoparticle and to 14% of mice treated with docetaxel alone (Farokhzad et al., 
2006). In a subsequent study, the cisplatin prodrug Pt(IV) was encapsulated in the anti-
PSMA nanoparticle. Endocytosis was detected using fluorescence microscopy by 
colocalization of the encapsulated green fluorescent labeled cholesterol with early endosome 
marker EEA-1. In a series of in vitro cytotoxic assays, the IC50 value was determined as 0.03 µM 
for the nanoparticele compared to 0.13 µM for the non-targeted nanoparticle and to 2.4 µM 
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for free cisplatin on LNCaP cells. However, a high background toxicity of the nanoparticle 
with an IC50 value of 0.11 µM was also detected on PSMA-negative PC-3 cells (Dhar et al., 
2008). In a recent study, the anti-PSMA aptamer based nanoparticle was optimized to a self-
assembly polymeric nanoparticle carrying cisplatin and docetaxel to prostate cancer cells 
with synergistic cytotoxicity. The controlled released of both chemotherapeutics was 
observed over a time period of 48 to 72 h and formation of cisplatin 1,2d(GpG) intrastrand 
crosslinks could be detected. In vitro cytotoxicity of the targeted nanoparticle with an IC50 
value of 0.09 µM on LNCaP cells was shown to be superior over single drug or non targeted 
nanoparticles (Kolishetti et al., 2010).  
Epigallocatechin 3-gallate (EGCG) is a green tea catechin, which has protective effects 
against some common types of cancer (Yang et al., 2009). Since it was shown to be 
chemopreventive against prostate cancer (Bettuzzi et al., 2006; Brausi et al., 2008), an EGCG 
loaded nanoparticle consisting of PLGA-PEG copolymers was functionalized with an urea-
based PSMA inhibitor (Sanna et al., 2011), which is capable of targeting PSMA with a similar 
affinity and specificity like antibodies and aptamers (Sanna et al., 2011). In in vitro 
experiments LNCaP cells were incubated for 1 or 3 h with the anti-PSMA nanoparticles. In 
this assay, a significant antiproliferative effect of the nanoparticles to the tumor cells, 
marked by a growth inhibition up to 60% after 72 h, could be measured (Sanna et al., 2011). 
3. Conclusion 
In the last years, PSMA arouse increasing interest as a prognostic and diagnostic 
biomarker as well as an attractive target antigen for new therapeutic approaches against 
prostate cancer. 
Anti-PSMA radioimmunoconjugates demonstrated efficient targeting of soft tissue and 
bone metastases and led to objective anti-tumor responses in a subset of patients. 
Moreover, high efficacy and tolerability of anti-PSMA immunotoxins was shown in many 
preclinical and clinical trials. The future strategy in this field is the recombinant 
production of immunotoxins, by which different limitations of chemically linked 
immunotoxins can be overcome.  
Retargeting of cytotoxic lymphocytes in vitro and in vivo led to anti-tumor activities in 
different preclinical studies. These effects could be enhanced by the evocation of 
costimulatory signaling. Additionally, early vaccination trials showed that an anti-PSMA 
immune response can be generated without general toxicity in prostate cancer patients.  
The development of PSMA-targeted prodrugs, photosensitizers and nanoparticles is still in 
an early stage, but such constructs also represent alternative therapeutics in the near future. 
It has to be considered that most of the discussed clinical treatments were tested in patients 
with advanced prostate cancer. However, as shown in preclinical trials, these new 
therapeutic drugs seem likely to be more effective in patients with minimal residual disease 
or metastases after primary therapies. 
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